

1. [Biosimilar 'wave' likely to hold out good prospects for Indian drug firms](#) – Hindu Business Line

An estimated \$ 55 billion worth of biosimilar drugs are expected to go off patents by 2020, and this opens the floodgates for Indian drug companies to partner, develop and manufacture such products, said Charu Manaktala, Senior Medical Director and Head of Clinical Strategy, Strategic Drug Development with Quintiles Asia, a multinational clinical research organisation.

The products whose patents expire between 2015 to 2020 include Humira, Enbrel, Rituxan, MabThera, Avastin, Herceptin and Remicade. Companies of all hues, including traditional big pharma, generic drugmakers biotech players and new entrants are joining this biosimilar “stampede”, Quintiles said.

Both the innovator companies and those that make the biosimilar products are making every effort to capture the market, she said, referring to the trastuzumab example in India. The breast cancer drug saw the innovator (Roche) drop price and partner with Indian companies to stave off competition from other Indian companies on the drug.

Similar article appeared in [The Hindu](#)

2. [Medical reps seek regulation of pharmaceutical industry](#) – The Hindu

The Karnataka State Medical and Sales Representatives' Association, affiliated to CITU, took out a rally and staged a demonstration at Ambedkar Circle here on Wednesday, seeking fulfilment of various demands related to supply and sale of medicines. “ Some pharmaceutical companies are indulging in malpractices for making more profits. The patients as end-users have to bear the brunt. The government should regulate the industry,,” Gururaj, secretary of the organisation, said.

3. [Indian drug market crosses Rs. 1 lk crore mark](#) – India Infoline

On the back of new drugs launched and enhanced R&D for drug discovery, the Indian pharmaceutical market has crossed Rs. 1,00,000 crore mark for the first time in November, according to a latest report by IMS Health. The market size is calculated based on the Moving Annual Total (MAT).

The monthly review by IMS Health revealed that for November, Indian drug firms took over 3/4 of the market share.

4. [Why Martin Shkreli's Price Hike May Hurt Everyone--Including You And The Pharmaceutical Industry](#) – Forbes

Why should you care if former hedge fund manager and current pharmaceutical executive Martin Shkreli plans to raise the price of benznidazole, a treatment for Chagas disease, by

1. [Biosimilar 'wave' likely to hold out good prospects for Indian drug firms](#) – Hindu Business Line

2. [Medical reps seek regulation of pharmaceutical industry](#) – The Hindu

3. [Indian drug market crosses Rs. 1 lk crore mark](#) – India Infoline

4. [Why Martin Shkreli's Price Hike May Hurt Everyone--Including You And The Pharmaceutical Industry](#) – Forbes

potentially over 100,000%? After all, as long as you or your family do not currently have Chagas disease, isn't this action similar to his paying \$2 million for a Wu-Tang Clan album: something that you would not approve of but probably does not affect you? Well, Wu-Tang clan albums are not exactly the same as medications. Massive price increases for any medication can affect many, many people and sectors, including you , regardless of how healthy you may be right now. And Chagas disease may affect you more than you realize . In fact, Shkreli's medication price hikes could end up hurting many industries and sectors, most notably the biotechnology and pharmaceutical industry.